Related Experiment Video
Updated: Aug 15, 2026
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Search of ligands for the amyloidogenic protein beta2-microglobulin by capillary electrophoresis and other techniques
Milena Quaglia1, Chiara Carazzone, Stefania Sabella
1Department of Pharmaceutical Chemistry, School of Pharmacy, University of Pavia, Italy. milena.quaglia@unipv.it
Abstract:
Beta2-microglobulin (beta2-m) is a small amyloidogenic protein normally present on the surface of most nucleated cells and responsible for dialysis-related amyloidosis, which represents a severe complication of long-term hemodialysis. A therapeutic approach for this amyloidosis could be based on the stabilization of beta2-m through the binding to a small molecule, and consequent inhibition of protein misfolding and amyloid fibril formation. A few compounds have been described to weakly bind beta2-m, including the drug suramin. The lack of a binding site for nonpolypeptidic ligands on the beta2-m structure makes it difficult for both the identification of functional groups responsible for the binding and the search of hits to be optimized. The characterization of the binding properties of suramin for beta2-m by using three different techniques (surface plasmon resonance, affinity CE (ACE), ultrafiltration) is here described and the results obtained are compared. The common features of the chemical structures of the compounds known to bind the protein led us to select 200 sulfonated/suramin-like molecules from a wider chemical library on the basis of similarity rules, so as to possibly single out some interesting hits and to gain more information on the functional groups involved in the binding. The development of screening methods to test the compounds by using ultrafiltration and ACE is described.
Insights
Researchers characterized beta2-microglobulin (beta2-m) binding with suramin to inhibit amyloidosis. They screened 200 similar molecules, developing new methods to identify potential therapeutic compounds for dialysis-related amyloidosis.
Area of Science:
- Biochemistry
- Medical Chemistry
- Nephrology
Background:
- Dialysis-related amyloidosis is a severe complication of long-term hemodialysis, caused by the amyloidogenic protein beta2-microglobulin (beta2-m).
- Stabilizing beta2-m with small molecules could inhibit protein misfolding and amyloid formation, offering a therapeutic strategy.
Purpose of the Study:
- To characterize the binding properties of suramin with beta2-m.
- To develop and apply screening methods for identifying novel small molecules that bind beta2-m.
- To gain insights into the functional groups involved in beta2-m binding.
Main Methods:
- Characterization of suramin-beta2-m binding using surface plasmon resonance, affinity capillary electrophoresis (ACE), and ultrafiltration.
- Selection of 200 sulfonated/suramin-like molecules based on structural similarity.
- Development of ultrafiltration and ACE-based screening assays for compound testing.
Main Results:
- Established binding characteristics between suramin and beta2-m using multiple biophysical techniques.
- Successfully developed and implemented screening assays for identifying potential beta2-m binders.
- Identified a library of candidate molecules for further optimization.
Conclusions:
- Suramin binding to beta2-m provides a basis for developing therapeutic strategies against dialysis-related amyloidosis.
- The developed screening methods are effective for identifying novel small molecule binders of beta2-m.
- Further investigation of the screened molecules may yield effective treatments for beta2-m amyloidosis.
More Related Videos
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
06:34A Tailored HPLC Purification Protocol That Yields High-purity Amyloid Beta 42 and Amyloid Beta 40 Peptides, Capable of Oligomer Formation
Published on: March 27, 2017